220 related articles for article (PubMed ID: 19217520)
1. Lipid management in patients who have HIV and are receiving HIV therapy.
Aberg JA
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):207-22. PubMed ID: 19217520
[TBL] [Abstract][Full Text] [Related]
2. Dyslipidemia in HIV-infected individuals.
Sprinz E; Lazzaretti RK; Kuhmmer R; Ribeiro JP
Braz J Infect Dis; 2010; 14(6):575-88. PubMed ID: 21340298
[TBL] [Abstract][Full Text] [Related]
3. Dyslipidemia and lipid management in HIV-infected patients.
Lo J
Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):144-7. PubMed ID: 21297466
[TBL] [Abstract][Full Text] [Related]
4. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.
Silverberg MJ; Leyden W; Hurley L; Go AS; Quesenberry CP; Klein D; Horberg MA
Ann Intern Med; 2009 Mar; 150(5):301-13. PubMed ID: 19258558
[TBL] [Abstract][Full Text] [Related]
5. Clinical management considerations for dyslipidemia in HIV-infected individuals.
Kirchner JT
Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
Samineni D; Fichtenbaum CJ
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):995-1004. PubMed ID: 20604734
[TBL] [Abstract][Full Text] [Related]
7. Dyslipidaemia associated with the highly active antiretroviral therapy in AIDS patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir).
Domingos H; da Cunha RV; Paniago AM
Braz J Infect Dis; 2007 Apr; 11(2):290-2. PubMed ID: 17625780
[TBL] [Abstract][Full Text] [Related]
8. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
Bain AM; White EA; Rutherford WS; Rahman AP; Busti AJ
Pharmacotherapy; 2008 Jul; 28(7):932-8. PubMed ID: 18576908
[TBL] [Abstract][Full Text] [Related]
9. Summaries for patients. Response to cholesterol-lowering drugs in patients with and without HIV infection.
Ann Intern Med; 2009 Mar; 150(5):I38. PubMed ID: 19258553
[No Abstract] [Full Text] [Related]
10. Human immunodeficiency virus and renal transplantation.
Dinavahi RV; Mehrotra A; Murphy BT; Huprikar S
Kidney Int; 2009 Oct; 76(8):907-10. PubMed ID: 19494802
[No Abstract] [Full Text] [Related]
11. Dyslipidemia related to antiretroviral therapy.
Estrada V; Portilla J
AIDS Rev; 2011; 13(1):49-56. PubMed ID: 21412389
[TBL] [Abstract][Full Text] [Related]
12. Dyslipidemia in HIV patients.
Tungsiripat M; Aberg JA
Cleve Clin J Med; 2005 Dec; 72(12):1113-20. PubMed ID: 16392725
[TBL] [Abstract][Full Text] [Related]
13. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.
Kotler DP
J Acquir Immune Defic Syndr; 2008 Sep; 49 Suppl 2():S79-85. PubMed ID: 18725816
[TBL] [Abstract][Full Text] [Related]
14. Treatment of dyslipidaemia in HIV-infected persons.
Manuel O; Thiébaut R; Darioli R; Tarr PE
Expert Opin Pharmacother; 2005 Aug; 6(10):1619-45. PubMed ID: 16086650
[TBL] [Abstract][Full Text] [Related]
15. Lipid metabolism in treated HIV Infection.
Dubé MP; Cadden JJ
Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
[TBL] [Abstract][Full Text] [Related]
16. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
[TBL] [Abstract][Full Text] [Related]
17. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.
Ahmed MH; Al-Atta A; Hamad MA
Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV.
Domingos H; Cunha RV; Paniago AM; Souza AS; Rodrigues RL; Domingos JA
Arq Bras Cardiol; 2012 Nov; 99(5):997-1007. PubMed ID: 23108642
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidemia and its Treatment in HIV Infection.
Grunfeld C
Top HIV Med; 2010; 18(3):112-8. PubMed ID: 20921577
[TBL] [Abstract][Full Text] [Related]
20. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
Tungsiripat M; Kitch D; Glesby MJ; Gupta SK; Mellors JW; Moran L; Jones L; Alston-Smith B; Rooney JF; Aberg JA
AIDS; 2010 Jul; 24(11):1781-4. PubMed ID: 20495438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
